Clinical Pharmacokinetics of Ombitasvir.

about

Clinical Pharmacokinetics of Paritaprevir.Clinical Pharmacokinetics of Dasabuvir.Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage.

P2860

Q39150134-D0BB9BA5-79EE-463F-8964-14B3BDD25656 Q39160612-6060596D-199E-4D8F-81EC-C05F4C4F866A Q47567111-3B148335-F7BC-4764-8082-14DDAEAB216C

P2860

Clinical Pharmacokinetics of Ombitasvir.

Item

http://www.wikidata.org/entity/Q39147495

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Clinical Pharmacokinetics of Ombitasvir.

@en

Clinical Pharmacokinetics of Ombitasvir.

@nl

type

Item

label

Clinical Pharmacokinetics of Ombitasvir.

@en

Clinical Pharmacokinetics of Ombitasvir.

@nl

prefLabel

Clinical Pharmacokinetics of Ombitasvir.

@en

Clinical Pharmacokinetics of Ombitasvir.

@nl

P1476

Clinical Pharmacokinetics of Ombitasvir.

@en

P2093

Diana L Shuster

http://www.w3.org/2001/XMLSchema#string

Prajakta S Badri

http://www.w3.org/2001/XMLSchema#string

Rajeev M Menon

http://www.w3.org/2001/XMLSchema#string

Sandeep Dutta

http://www.w3.org/2001/XMLSchema#string

P2860

Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy

Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir

Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir

Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and Rilpivirine

Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers.

Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir

Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine

In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A.

Clinical Pharmacokinetics of Paritaprevir.

Clinical Pharmacokinetics of Dasabuvir.

P2888

s40262-017-0518-4

P31

scholarly article

P356

10.1007/S40262-017-0518-4

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28229375

http://www.w3.org/2001/XMLSchema#string

P921

ombitasvir

Clinical Pharmacokinetics of Ombitasvir.

about

P2860

P2860

Clinical Pharmacokinetics of Ombitasvir.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P31

P356

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P31

P356

P577

P698

P921